Compile Data Set for Download or QSAR

Found 37 hits with Last Name = 'habermann' and Initial = 'c'   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342149 (1-((2-(tert-butyl)-4-(3-chlorophenyl)thiazol-5-yl)...) Show SMILES CC(C)(C)c1nc(c(CNC(=O)Nc2cccc3cnccc23)s1)-c1cccc(Cl)c1 Show InChI InChI=1S/C24H23ClN4OS/c1-24(2,3)22-29-21(15-6-4-8-17(25)12-15)20(31-22)14-27-23(30)28-19-9-5-7-16-13-26-11-10-18(16)19/h4-13H,14H2,1-3H3,(H2,27,28,30)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.100	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342128 (N-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...) Show SMILES CC(C(=O)NCc1sc(nc1-c1cccc(Cl)c1)C(F)(F)F)c1cnc(CO)c(F)c1 Show InChI InChI=1S/C20H16ClF4N3O2S/c1-10(12-6-14(22)15(9-29)26-7-12)18(30)27-8-16-17(11-3-2-4-13(21)5-11)28-19(31-16)20(23,24)25/h2-7,10,29H,8-9H2,1H3,(H,27,30)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.300	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342122 (N-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...) Show SMILES CC(C(=O)NCc1sc(nc1-c1cccc(Cl)c1)C(F)(F)F)c1ccc(NCCO)nc1 Show InChI InChI=1S/C21H20ClF3N4O2S/c1-12(14-5-6-17(27-10-14)26-7-8-30)19(31)28-11-16-18(13-3-2-4-15(22)9-13)29-20(32-16)21(23,24)25/h2-6,9-10,12,30H,7-8,11H2,1H3,(H,26,27)(H,28,31)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.400	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342117 (N-((2-(tert-butyl)-4-(3-chlorophenyl)thiazol-5-yl)...) Show SMILES CC(C(=O)NCc1sc(nc1-c1cccc(Cl)c1)C(C)(C)C)c1ccc(CNS(C)(=O)=O)c(F)c1 Show InChI InChI=1S/C25H29ClFN3O3S2/c1-15(16-9-10-18(20(27)12-16)13-29-35(5,32)33)23(31)28-14-21-22(17-7-6-8-19(26)11-17)30-24(34-21)25(2,3)4/h6-12,15,29H,13-14H2,1-5H3,(H,28,31)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.600	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342119 (N-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...) Show SMILES CC(C(=O)NCc1sc(nc1-c1cccc(Cl)c1)C(F)(F)F)c1ccc(CNS(N)(=O)=O)cc1 Show InChI InChI=1S/C21H20ClF3N4O3S2/c1-12(14-7-5-13(6-8-14)10-28-34(26,31)32)19(30)27-11-17-18(15-3-2-4-16(22)9-15)29-20(33-17)21(23,24)25/h2-9,12,28H,10-11H2,1H3,(H,27,30)(H2,26,31,32)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.700	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342122 (N-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...) Show SMILES CC(C(=O)NCc1sc(nc1-c1cccc(Cl)c1)C(F)(F)F)c1ccc(NCCO)nc1 Show InChI InChI=1S/C21H20ClF3N4O2S/c1-12(14-5-6-17(27-10-14)26-7-8-30)19(31)28-11-16-18(13-3-2-4-15(22)9-13)29-20(32-16)21(23,24)25/h2-6,9-10,12,30H,7-8,11H2,1H3,(H,26,27)(H,28,31)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.700	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342121 (N-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...) Show SMILES CC(C(=O)NCc1oc(nc1-c1cccc(Cl)c1)C(F)(F)F)c1ccc(NCCO)nc1 Show InChI InChI=1S/C21H20ClF3N4O3/c1-12(14-5-6-17(27-10-14)26-7-8-30)19(31)28-11-16-18(13-3-2-4-15(22)9-13)29-20(32-16)21(23,24)25/h2-6,9-10,12,30H,7-8,11H2,1H3,(H,26,27)(H,28,31)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.700	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342120 (N-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...) Show SMILES CC(C(=O)NCc1sc(nc1-c1cccc(Cl)c1)C(F)(F)F)c1cnc(CCS(C)(=O)=O)c(F)c1 Show InChI InChI=1S/C22H20ClF4N3O3S2/c1-12(14-9-16(24)17(28-10-14)6-7-35(2,32)33)20(31)29-11-18-19(13-4-3-5-15(23)8-13)30-21(34-18)22(25,26)27/h3-5,8-10,12H,6-7,11H2,1-2H3,(H,29,31)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1.10	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342115 (N-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...) Show SMILES CC(C(=O)NCc1sc(nc1-c1cccc(Cl)c1)C(F)(F)F)c1ccc(CCO)c(F)c1 Show InChI InChI=1S/C22H19ClF4N2O2S/c1-12(14-6-5-13(7-8-30)17(24)10-14)20(31)28-11-18-19(15-3-2-4-16(23)9-15)29-21(32-18)22(25,26)27/h2-6,9-10,12,30H,7-8,11H2,1H3,(H,28,31)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	1.40	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342151 (N-(4-(3-((2-(tert-butyl)-4-(m-tolyl)thiazol-5-yl)m...) Show SMILES Cc1cccc(c1)-c1nc(sc1CNC(=O)Nc1ccc(CNS(C)(=O)=O)c(F)c1)C(C)(C)C Show InChI InChI=1S/C24H29FN4O3S2/c1-15-7-6-8-16(11-15)21-20(33-22(29-21)24(2,3)4)14-26-23(30)28-18-10-9-17(19(25)12-18)13-27-34(5,31)32/h6-12,27H,13-14H2,1-5H3,(H2,26,28,30)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	2.30	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342130 (N-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...) Show SMILES CC(C(=O)NCc1sc(nc1-c1cccc(Cl)c1)C(F)(F)F)c1ccc(CNS(N)(=O)=O)c(F)c1 Show InChI InChI=1S/C21H19ClF4N4O3S2/c1-11(12-5-6-14(16(23)8-12)9-29-35(27,32)33)19(31)28-10-17-18(13-3-2-4-15(22)7-13)30-20(34-17)21(24,25)26/h2-8,11,29H,9-10H2,1H3,(H,28,31)(H2,27,32,33)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	2.35	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342129 (N-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...) Show SMILES CC(C(=O)NCc1oc(nc1-c1cccc(Cl)c1)C(F)(F)F)c1ccc(CNS(N)(=O)=O)c(F)c1 Show InChI InChI=1S/C21H19ClF4N4O4S/c1-11(12-5-6-14(16(23)8-12)9-29-35(27,32)33)19(31)28-10-17-18(13-3-2-4-15(22)7-13)30-20(34-17)21(24,25)26/h2-8,11,29H,9-10H2,1H3,(H,28,31)(H2,27,32,33)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	4.70	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342121 (N-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...) Show SMILES CC(C(=O)NCc1oc(nc1-c1cccc(Cl)c1)C(F)(F)F)c1ccc(NCCO)nc1 Show InChI InChI=1S/C21H20ClF3N4O3/c1-12(14-5-6-17(27-10-14)26-7-8-30)19(31)28-11-16-18(13-3-2-4-15(22)9-13)29-20(32-16)21(23,24)25/h2-6,9-10,12,30H,7-8,11H2,1H3,(H,26,27)(H,28,31)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	5.20	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342147 (1-((2-(tert-butyl)-4-(3-chlorophenyl)thiazol-5-yl)...) Show SMILES CC(C)(C)c1nc(c(CNC(=O)Nc2ccc3OCCOc3c2)s1)-c1cccc(Cl)c1 Show InChI InChI=1S/C23H24ClN3O3S/c1-23(2,3)21-27-20(14-5-4-6-15(24)11-14)19(31-21)13-25-22(28)26-16-7-8-17-18(12-16)30-10-9-29-17/h4-8,11-12H,9-10,13H2,1-3H3,(H2,25,26,28)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	5.90	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342150 (N-(4-(3-((2-(tert-butyl)-4-(3-chlorophenyl)thiazol...) Show SMILES CC(C)(C)c1nc(c(CNC(=O)Nc2ccc(CNS(C)(=O)=O)c(F)c2)s1)-c1cccc(Cl)c1 Show InChI InChI=1S/C23H26ClFN4O3S2/c1-23(2,3)21-29-20(14-6-5-7-16(24)10-14)19(33-21)13-26-22(30)28-17-9-8-15(18(25)11-17)12-27-34(4,31)32/h5-11,27H,12-13H2,1-4H3,(H2,26,28,30)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	6.60	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342118 (N-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...) Show SMILES CC(C(=O)NCc1oc(nc1-c1cccc(Cl)c1)C(F)(F)F)c1ccc(CNS(N)(=O)=O)cc1 Show InChI InChI=1S/C21H20ClF3N4O4S/c1-12(14-7-5-13(6-8-14)10-28-34(26,31)32)19(30)27-11-17-18(15-3-2-4-16(22)9-15)29-20(33-17)21(23,24)25/h2-9,12,28H,10-11H2,1H3,(H,27,30)(H2,26,31,32)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	7.5	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342144 (N-((5-(3-chlorophenyl)-2-(tertbutyl)thiazol-5-yl)m...) Show SMILES CC(C)(C)C1SC(CNC(=O)Nc2ccc(CNS(N)(=O)=O)cc2)(C=N1)c1cccc(Cl)c1 |c:25| Show InChI InChI=1S/C22H28ClN5O3S2/c1-21(2,3)19-25-13-22(32-19,16-5-4-6-17(23)11-16)14-26-20(29)28-18-9-7-15(8-10-18)12-27-33(24,30)31/h4-11,13,19,27H,12,14H2,1-3H3,(H2,24,30,31)(H2,26,28,29)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	9.10	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342148 (1-((2-(tert-butyl)-4-(3-chlorophenyl)thiazol-5-yl)...) Show SMILES CC(C)(C)c1nc(c(CNC(=O)Nc2ccc3CCCc3c2)s1)-c1cccc(Cl)c1 Show InChI InChI=1S/C24H26ClN3OS/c1-24(2,3)22-28-21(17-8-5-9-18(25)12-17)20(30-22)14-26-23(29)27-19-11-10-15-6-4-7-16(15)13-19/h5,8-13H,4,6-7,14H2,1-3H3,(H2,26,27,29)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	12.3	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342127 (N-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...) Show SMILES CC(C(=O)NCc1oc(nc1-c1cccc(Cl)c1)C(F)(F)F)c1cnc(CO)c(F)c1 Show InChI InChI=1S/C20H16ClF4N3O3/c1-10(12-6-14(22)15(9-29)26-7-12)18(30)27-8-16-17(11-3-2-4-13(21)5-11)28-19(31-16)20(23,24)25/h2-7,10,29H,8-9H2,1H3,(H,27,30)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	13.8	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342138 (N-(4-(3-((2-(tert-butyl)-4-(3-fluorophenyl)thiazol...) Show SMILES CC(C)(C)c1nc(c(CNC(=O)Nc2ccc(CNS(C)(=O)=O)cc2)s1)-c1cccc(F)c1 Show InChI InChI=1S/C23H27FN4O3S2/c1-23(2,3)21-28-20(16-6-5-7-17(24)12-16)19(32-21)14-25-22(29)27-18-10-8-15(9-11-18)13-26-33(4,30)31/h5-12,26H,13-14H2,1-4H3,(H2,25,27,29)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	17.6	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342132 (1-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...) Show SMILES OCc1ccc(NC(=O)NCc2sc(nc2-c2cccc(Cl)c2)C(F)(F)F)cn1 Show InChI InChI=1S/C18H14ClF3N4O2S/c19-11-3-1-2-10(6-11)15-14(29-16(26-15)18(20,21)22)8-24-17(28)25-12-4-5-13(9-27)23-7-12/h1-7,27H,8-9H2,(H2,24,25,28)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	19.4	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342135 (1-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...) Show SMILES OC1CN(C1)c1ccc(NC(=O)NCc2sc(nc2-c2cccc(Cl)c2)C(F)(F)F)cn1 Show InChI InChI=1S/C20H17ClF3N5O2S/c21-12-3-1-2-11(6-12)17-15(32-18(28-17)20(22,23)24)8-26-19(31)27-13-4-5-16(25-7-13)29-9-14(30)10-29/h1-7,14,30H,8-10H2,(H2,26,27,31)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	24.6	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342140 (1-((2-(tert-butyl)-4-(3-chlorophenyl)thiazol-5-yl)...) Show SMILES CC(C)(C)c1nc(c(CNC(=O)Nc2ccc(OCCO)nc2)s1)-c1cccc(Cl)c1 Show InChI InChI=1S/C22H25ClN4O3S/c1-22(2,3)20-27-19(14-5-4-6-15(23)11-14)17(31-20)13-25-21(29)26-16-7-8-18(24-12-16)30-10-9-28/h4-8,11-12,28H,9-10,13H2,1-3H3,(H2,25,26,29)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	27.5	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342116 (N-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...) Show SMILES CC(C(=O)NCc1oc(nc1-c1cccc(Cl)c1)C(F)(F)F)c1ccc(CCO)c(F)c1 Show InChI InChI=1S/C22H19ClF4N2O3/c1-12(14-6-5-13(7-8-30)17(24)10-14)20(31)28-11-18-19(15-3-2-4-16(23)9-15)29-21(32-18)22(25,26)27/h2-6,9-10,12,30H,7-8,11H2,1H3,(H,28,31)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	28.4	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342142 (1-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...) Show SMILES OCCOc1ccc(NC(=O)NCc2sc(nc2-c2cccc(Cl)c2)C(F)(F)F)cn1 Show InChI InChI=1S/C19H16ClF3N4O3S/c20-12-3-1-2-11(8-12)16-14(31-17(27-16)19(21,22)23)10-25-18(29)26-13-4-5-15(24-9-13)30-7-6-28/h1-5,8-9,28H,6-7,10H2,(H2,25,26,29)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	29.8	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342143 (N-((5-(3-chlorophenyl)-2-(tertbutyl)oxazol-4-yl)me...) Show SMILES CC(C)(C)c1nc(CNC(=O)Nc2ccc(CNS(N)(=O)=O)cc2)c(o1)-c1cccc(Cl)c1 Show InChI InChI=1S/C22H26ClN5O4S/c1-22(2,3)20-28-18(19(32-20)15-5-4-6-16(23)11-15)13-25-21(29)27-17-9-7-14(8-10-17)12-26-33(24,30)31/h4-11,26H,12-13H2,1-3H3,(H2,24,30,31)(H2,25,27,29)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	29.9	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342145 (1-((2-(tert-butyl)-4-(3-chlorophenyl)thiazol-5-yl)...) Show SMILES CC(C)(C)c1nc(c(CNC(=O)Nc2ccc(COCCO)nc2)s1)-c1cccc(Cl)c1 Show InChI InChI=1S/C23H27ClN4O3S/c1-23(2,3)21-28-20(15-5-4-6-16(24)11-15)19(32-21)13-26-22(30)27-17-7-8-18(25-12-17)14-31-10-9-29/h4-8,11-12,29H,9-10,13-14H2,1-3H3,(H2,26,27,30)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	33.3	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342146 (1-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...) Show SMILES OCCOCc1ccc(NC(=O)NCc2sc(nc2-c2cccc(Cl)c2)C(F)(F)F)cn1 Show InChI InChI=1S/C20H18ClF3N4O3S/c21-13-3-1-2-12(8-13)17-16(32-18(28-17)20(22,23)24)10-26-19(30)27-14-4-5-15(25-9-14)11-31-7-6-29/h1-5,8-9,29H,6-7,10-11H2,(H2,26,27,30)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	35	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342122 (N-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...) Show SMILES CC(C(=O)NCc1sc(nc1-c1cccc(Cl)c1)C(F)(F)F)c1ccc(NCCO)nc1 Show InChI InChI=1S/C21H20ClF3N4O2S/c1-12(14-5-6-17(27-10-14)26-7-8-30)19(31)28-11-16-18(13-3-2-4-15(22)9-13)29-20(32-16)21(23,24)25/h2-6,9-10,12,30H,7-8,11H2,1H3,(H,26,27)(H,28,31)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	41.9	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342139 (1-((2-(tert-butyl)-4-(3-chlorophenyl)oxazol-5-yl)m...) Show SMILES CC(C)(C)c1nc(c(CNC(=O)Nc2ccc(OCCO)nc2)o1)-c1cccc(Cl)c1 Show InChI InChI=1S/C22H25ClN4O4/c1-22(2,3)20-27-19(14-5-4-6-15(23)11-14)17(31-20)13-25-21(29)26-16-7-8-18(24-12-16)30-10-9-28/h4-8,11-12,28H,9-10,13H2,1-3H3,(H2,25,26,29)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	43.6	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342133 (1-((4-(3-chlorophenyl)-2-(trifluoromethyl)thiazol-...) Show SMILES CS(=O)(=O)CCc1ccc(NC(=O)NCc2sc(nc2-c2cccc(Cl)c2)C(F)(F)F)cn1 Show InChI InChI=1S/C20H18ClF3N4O3S2/c1-33(30,31)8-7-14-5-6-15(10-25-14)27-19(29)26-11-16-17(12-3-2-4-13(21)9-12)28-18(32-16)20(22,23)24/h2-6,9-10H,7-8,11H2,1H3,(H2,26,27,29)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	48.8	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342137 (N-(4-(3-((2-(tert-butyl)-4-(3-chlorophenyl)oxazol-...) Show SMILES CC(C)(C)c1nc(c(CNC(=O)Nc2ccc(CNS(C)(=O)=O)cc2)o1)-c1cccc(Cl)c1 Show InChI InChI=1S/C23H27ClN4O4S/c1-23(2,3)21-28-20(16-6-5-7-17(24)12-16)19(32-21)14-25-22(29)27-18-10-8-15(9-11-18)13-26-33(4,30)31/h5-12,26H,13-14H2,1-4H3,(H2,25,27,29)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	52.6	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342134 (1-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...) Show SMILES OC1CN(C1)c1ccc(NC(=O)NCc2oc(nc2-c2cccc(Cl)c2)C(F)(F)F)cn1 Show InChI InChI=1S/C20H17ClF3N5O3/c21-12-3-1-2-11(6-12)17-15(32-18(28-17)20(22,23)24)8-26-19(31)27-13-4-5-16(25-7-13)29-9-14(30)10-29/h1-7,14,30H,8-10H2,(H2,26,27,31)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	60.8	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342131 (1-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...) Show SMILES OCc1ccc(NC(=O)NCc2oc(nc2-c2cccc(Cl)c2)C(F)(F)F)cn1 Show InChI InChI=1S/C18H14ClF3N4O3/c19-11-3-1-2-10(6-11)15-14(29-16(26-15)18(20,21)22)8-24-17(28)25-12-4-5-13(9-27)23-7-12/h1-7,27H,8-9H2,(H2,24,25,28)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	62.5	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342136 (1-((2-(tert-butyl)-4-(3-chlorophenyl)oxazol-5-yl)m...) Show SMILES CC(C)(C)c1nc(c(CNC(=O)Nc2ccc(CCO)nc2)o1)-c1cccc(Cl)c1 Show InChI InChI=1S/C22H25ClN4O3/c1-22(2,3)20-27-19(14-5-4-6-15(23)11-14)18(30-20)13-25-21(29)26-17-8-7-16(9-10-28)24-12-17/h4-8,11-12,28H,9-10,13H2,1-3H3,(H2,25,26,29)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	78.4	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342121 (N-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...) Show SMILES CC(C(=O)NCc1oc(nc1-c1cccc(Cl)c1)C(F)(F)F)c1ccc(NCCO)nc1 Show InChI InChI=1S/C21H20ClF3N4O3/c1-12(14-5-6-17(27-10-14)26-7-8-30)19(31)28-11-16-18(13-3-2-4-15(22)9-13)29-20(32-16)21(23,24)25/h2-6,9-10,12,30H,7-8,11H2,1H3,(H,26,27)(H,28,31)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	96.7	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair
Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human))	BDBM342141 (1-((4-(3-chlorophenyl)-2-(trifluoromethyl)oxazol-5...) Show SMILES OCCOc1ccc(NC(=O)NCc2oc(nc2-c2cccc(Cl)c2)C(F)(F)F)cn1 Show InChI InChI=1S/C19H16ClF3N4O4/c20-12-3-1-2-11(8-12)16-14(31-17(27-16)19(21,22)23)10-25-18(29)26-13-4-5-15(24-9-13)30-7-6-28/h1-5,8-9,28H,6-7,10H2,(H2,25,26,29)	PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	103	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Medifron DBT Inc. US Patent					Assay Description The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...				US Patent US9771359 (2017) BindingDB Entry DOI: 10.7270/Q2CZ3984
					More data for this Ligand-Target Pair